登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>4-1BB >41B-M5258

Mouse 4-1BB /TNFRSF9 Protein, Fc Tag (MALS verified)

分子别名(Synonym)

TNFRSF9,4-1BB,CD137,CDw137,ILA

表达区间及表达系统(Source)

Mouse 4-1BB, Fc Tag (41B-M5258) is expressed from human 293 cells (HEK293). It contains AA Val 24 - Leu 211 (Accession # Q8R037-1).

Predicted N-terminus: Val 24

Request for sequence

蛋白结构(Molecular Characterization)

4-1BB Structure

This protein carries a human IgG1 Fc tag at the C-terminus

The protein has a calculated MW of 46.7 kDa. The protein migrates as 50-66 kDa under reducing (R) condition (SDS-PAGE).

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

4-1BB SDS-PAGE

Mouse 4-1BB, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS

4-1BB SEC-MALS

The purity of Mouse 4-1BB, Fc Tag (Cat. No. 41B-M5258) is more than 90% and the molecular weight of this protein is around 110-130 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

4-1BB ELISA

Immobilized Mouse 4-1BB, Fc Tag (Cat. No. 41B-M5258) at 2 μg/mL (100 μL/well) can bind Human 4-1BB Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. 41L-H5254) with a linear range of 20-312 ng/mL (QC tested).

Protocol

4-1BB ELISA

Immobilized Mouse 4-1BB, Fc Tag (Cat. No. 41B-M5258) at 2 μg/mL (100 μL/well) can bind Biotinylated Human 4‑1BB Ligand, Fc Tag, Avi Tag (Cat. No. 41L-H82F9) with a linear range of 0.01-0.156 μg/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

4-1BB BLI

Loaded Mouse 4-1BB, Fc Tag (Cat. No. 41B-M5258) on Protein A Biosensor, can bind Human 4-1BB Ligand (71-254), His,Flag Tag (active trimer) (MALS verified) (Cat. No. 41L-H52D4) with an affinity constant of 18.6 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 

背景(Background)

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
4-1BB靶点信息
英文全称:Tumor necrosis factor receptor superfamily member 9
中文全称:肿瘤坏死因子受体超家族成员9
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:65详情
最高研发阶段:临床三期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定